The Power of Genome Editing: What Investors Should Know

The cost of sequencing a human genome has dropped significantly over the past years and genome editing is enabling new breakthroughs in medicine. ARK believes that CRISPR is biotech’s breakthrough of the century and that it will have a profound impact on the world’s most salient issues, especially as its toolbox expands. Based on ARK’s research, CRISPR’s addressable market in the monogenic disease space totals over $75 billion annually with nearly $2 trillion in latent demand from unaddressed populations.

December 04, 2018
11am PST | 2pm EST
1 CE Credit
Register Now!

*Denotes required

You must have Javascript and Cookies enabled to access this webcast. Click here for Help.

Already Registered? Click here »


Join ARK Invest and Tom Lydon, Editor and Publisher of ETF Trends as he moderates a discussion on:

  • How innovation is driving the space
  • The impact of genome-editing and immunotherapy on human therapeutics
  • Latest updates on CRISPR research breakthroughs
  • How financial advisors can capture the genomic opportunity
  • How investors can enhance portfolios with innovation-focused strategies

Not accepted for one hour of CFP/CIMA CE credit for live and on-demand attendees

CFA Institute members are encouraged to self-document their continuing professional development activities in their online CE tracker.


Manisha Samy

Analyst Genomic Revolution
ARK Invest

Renato Leggi

Client Portfolio Manager
ARK Invest

Tom Lydon

Editor and Publisher
ETF Trends

By registering, you are certifying that you are a financial professional and agree to share your data with ETF Trends and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the ETF Trends' Privacy Policy. You can unsubscribe at any time.